Adverse outcome pathways (AOP) and mode of action (MOA) frameworks help evaluate the toxicity findings of animal studies and their relevance to humans. To effectively use these tools to improve hazard identification and risk assessments for ethyl acrylate (EA), knowledge gaps in metabolism and genotoxicity were identified and addressed. For EA, hypothesized early key events relate to its irritation potential: concentration dependent irritation and cytotoxicity, progressing to regenerative proliferation and forestomach carcinogenicity after repeated oral bolus application in rodents. The current research quantitated glutathione (GSH) depletion to assess a kinetically-derived maximum tolerated dose (MTD) in the target tissue and used this information to conduct an in vivo genotoxicity study using current methods. In the mouse forestomach, gavage doses of EA caused GSH depletion to 47% of control at 20 mg/kg and 28% at 100 mg/kg. Cellular redox changes and histopathology support saturation of metabolism and an MTD of ∼50 mg/kg. No increases in point mutations or deletions occurred in the stomach or liver following a 28 day treatment of gpt delta transgenic mice at gavage doses up to 50 mg/kg/day. These results provide valuable information for evaluating AOP molecular initiating events or MOA key events for EA and other GSH depleting materials.
Introduction
Adverse outcome pathways (AOP) and mode of action (MOA) frameworks are being developed to help determine the in depth understanding of the findings of animal studies and their relevance to humans. An AOP is a conceptual framework that portrays existing knowledge concerning the linkage between a direct molecular initiating event (MIE) and an adverse outcome at a level of biological organization relevant to risk assessment (Ankley et al., 2010) . Similarly, an MOA framework relies on the assumption that any health effect caused by exposure to a substance can be described by a series of causally linked biochemical or biological key events (KE) that result in an observed specified outcome (Meek et al., 2014) . Both are tools to develop, organize, assess, and improve the understanding of the stressors leading to adverse outcomes in health and environmental risk assessments. The MIE in an AOP is a starting point, like the initial key event in an MOA. The MOA analysis begins with a specific scenario, identifying the substance, exposure, and effect. Listing the KE, arranging them in the likely sequence of occurrence and establishing a dose response pattern build the framework that can be analyzed. Guidance stresses the utility of applying modified Bradford-Hill criteria when considering KE and the data that support their position in the framework. An important consideration regarding the dose response relationship includes determination whether the KE are observed before, concurrent with, or after the toxic outcome is expressed. AOPs, on the other hand, are not intended to be chemical specific, but rather conceptually applied to any stressor that initiates a series of events, progressing from the molecular to cellular to organ to organism to population level. In this regard, AOPs are modular, and can describe a variety of pathways depending on the sequence of events occurring.
Consideration of the next steps to improve the hazard and risk assessments for ethyl acrylate (EA, included use of these tools to understand the relevance to humans of adverse outcomes identified in animal studies, including tumor and non-tumor findings. To that end, the existing animal database was evaluated against the available guidance in the MOA/species concordance analysis framework (Meek et al., 2014; Boobis et al., 2009) . EA is a chemical substance that produced forestomach tumors in rodents via oral gavage, an adverse outcome for which an MOA framework (Proctor et al., 2007) was proposed and AOP analyses (AOP Wiki) are ongoing. In the case of EA, early KE are hypothesized to be related to the irritant characteristics of the substance which determine the dose response and the recovery relationship after acute and chronic exposure. These include concentration dependent irritation and cytotoxicity, with progression to more serious regenerative proliferation and even carcinogenicity under certain circumstances. The analyses are intended to focus on the contributing factors to each KE or MIE, and elucidation of circumstances that influence the outcome. Of particular interest for EA are the outcomes before and after exposure to irritating or cytotoxic doses, and reliably predicting the maximum tolerated dose of the substance under various testing regimens, including the chronic bioassays that resulted in forestomach tumors. An IARC technical report (2003) stated that the relevance of rodent forestomach tumors to humans is "probably limited for agents that have no demonstrable genotoxicity and that are solely carcinogenic for the forestomach squamous epithelium in rodents after oral administration". The Proctor et al. (2007) review included EA among the examples, providing the assessment: "Tumor promulgation with cessation of exposure is another key consideration. Kagawa et al. (1993) demonstrated that forestomach lesions induced by genotoxic carcinogens did not regress with removal of exposure, while simple or papillary hyperplasia induced by nongenotoxic carcinogens did regress after cessation of exposure. Ghanayem et al. (1994) showed that forestomach epithelial hyperplasia continued as long as exposure to EA continued via gavage dosing, but cessation of exposure resulted in the regression of hyperplasia and lack of tumor development. Therefore, the effect of temporal dosing regimens on forestomach tumor development should be considered in assessing the MOA and relevance to human exposures."
As a high volume material, EA has a comprehensive traditional toxicology database of in vivo and in vitro studies (ECHA, 2016; McLaughlin et al., 1993; OECD, 2005) . The predominant adverse findings include skin sensitization and strong irritation to all tissues upon immediate contact. Systemic toxicity was only observed at lethal doses. Chronic drinking water (Borzelleca et al., 1964) , inhalation (Miller et al., 1985) , and dermal (DePass et al., 1984) studies did not produce increases in tumor incidence. EA produced forestomach tumors in rats and mice after chronic administration by oral gavage (NTP, 1986) . No other tumors were observed. The formation of the forestomach tumors was preceded by dose related chronic irritation, inflammation, hyperkeratosis and hyperplasia of the forestomach in both sexes of both species tested. The dermal and inhalation routes of administration are most relevant to workplace exposures, and notably EA was not carcinogenic by these exposure routes.
After the bioassays revealed forestomach tumors, mechanistic data for EA were developed primarily in the rat, with emphasis on metabolism, genotoxicity, and physiologically based pharmacokinetic (PBPK) modeling. Metabolism of EA occurs in two major pathways: carboxylesterase mediated hydrolysis and conjugation with glutathione (GSH). Radiolabeled EA was rapidly eliminated after oral administration to rats (deBethizy et al., 1987) . Most was hydrolyzed, and the remainder was conjugated with nonprotein sulfhydryls (NPSH) such as GSH with mercapturic-acid derivatives excreted in the urine. After gavage administration, dose related depletion of NPSH in forestomach and glandular stomach was observed, with maximum efficiency of conjugation to be at less than 20 mg/kg, citing a precipitous drop in NPSH content at the dosing site between 2 and 20 mg/kg. At > 100 mg/kg the NPSH content did not change with dose, suggesting that reactive thiols were depleted. In vitro studies using cell free systems have shown that Michael addition of EA with GSH can occur in the absence of glutathione S-transferase enzyme (McCarthy et al., 1994) while enzyme-catalyzed GSH conjugation has been shown in a variety of tissue homogenates (Potter and Tran, 1992) . Importantly, following GSH adduct formation no reactive chemical bonds will remain in the conjugate due to the lack of a bond available for further Michael additions. Frederick et al. (1992) described that rapid detoxification of EA prevents toxic responses occurring in tissues remote from the dosing site. Significant GSH depletion was associated with the toxic response only at the site of gavage dosing. In time course studies forestomach GSH levels recovered from acute insult and returned to normal within several days, suggesting that when recovery is possible, rapid detoxification can be expected. Stimulation of S-phase activity in the forestomach and glandular stomach correlated with the replenishment and overshoot of tissue NPS levels with differences in the responses of the two tissues (Gillette and Frederick, 1993) . After two weeks of administration the forestomach tissue appeared to have significantly increased detoxification potential (NPS level) at doses up to 50 mg/kg, but at 200 mg/kg dramatic proliferative activity was noted. The glandular stomach, a non-target tissue, showed only a marginal S phase increase at 200 mg/kg, reflecting more effective detoxification processes.
Comprehensive reviews of the genotoxicity data related to mechanisms of carcinogenesis for EA are available in the literature (Heine and Schneider, 2012; Johannsen et al., 2008; WHO, 2006; Williams and Iatropoulos, 2009 ). The weight of evidence indicates that EA does not present a genotoxic hazard to humans.
Electrophiles such as EA (Freidig et al., 2001 ) can form GSH conjugates irreversibly consuming a substantial portion of cellular GSH. Below a certain critical threshold, depletion of GSH impairs cellular protective mechanisms resulting in cytotoxicity (Lushchak, 2012; Lu, 2009) . Mechanistic studies using mouse lymphoma cells indicated that the EA-induced mutagenic response in vitro correlated best with cellular cytotoxicity mediated by NPSH depletion and mitochondrial membrane impairment, rather than a direct DNA effect (Ciaccio et al., 1998) . This aligns with the report by Morimoto et al. (1990) that no DNA damage was noted in the forestomach of F344 rats after single gavage doses of EA. This also supports GSH depletion as evidence of saturation of metabolism, as an MIE or initial KE that adequately defines the maximum tolerated dose (MTD) for tissues in which this pathway is crucial.
Critical review of each hypothesized MOA and the data that support the KE often identifies gaps in the data, particularly if there are multiple plausible pathways to a given endpoint. Despite the extensive data base for EA, data gaps existed in the areas of in vivo mutagenicity and dose related quantitation of GSH depletion in the mouse forestomach. The following studies were undertaken to determine the extent of GSH depletion as an indicator of cellular toxicity in the forestomach of rats and mice after exposure to EA and to understand the role of GSH in determining the MTD in this and other tissues and then to generate contemporary guideline (OECD 488) compliant mutation data with doses not exceeding the MTD. Corn oil suspensions were prepared to achieve the targeted dose levels for mice at a dose volume of 10 mL/kg bw and rats at 5 mL/kg. The control mice were dosed with corn oil at 10 mL/kg and rats at 5 mL/kg. 2.1.3 Test Systems: Male F344/DuCrl rats, which were used in previous pharmacokinetic studies with EA (Frederick et al., 1992) and male C57BL/6 mice, the same background strain used in the EA Transgenic Rodent Gene Mutation assay (see below) were purchased from Charles River, Kingston (NY, USA). Animals were approximately 7 weeks old at study. 2.1.4 Non-GLP Range Finding Study: Groups of 3 mice were administered a single dose of EA by gavage at 0, 50, or 100 mg/kg body weight (mg/kg bw) in corn oil. Mice were sacrificed approximately 1 or 3 h after dosing. Mice were anesthetized via isoflurane/O 2 followed by carbon dioxide and decapitation. The forestomach was removed, weighed, flash frozen in liquid nitrogen, and placed in a −80°C freezer until analysis for GSH and glutathione disulfide (GSSG) levels. 2.1.5 GLP GSH & GSSG Studies: 5 mice/group were administered a gavage dose of EA at 0, 20, 50, or 100 mg/kg bw in corn oil. 3 h later, all mice were sacrificed and samples were processed as described above. 5 rats/group were administered 20 mg/kg EA by gavage. 3 h later, all rats were sacrificed and samples were processed as described for mice. 2.1.6 GSH:GSSG analyses: The frozen forestomaches were thawed, homogenized, and extracted with 10% trichloroacetic acid (TCA) on dry ice. Extracts were further diluted based on GSH or GSSG detection limit requirements and analyzed using high performance liquid chromatography and positive ion electrospray ionization, tandem mass spectrometry detection operating in multiple reaction ion monitoring mode (HPLC/+ESI/MS/MS). The concentration of GSH and GSSG was determined using calibrated stable isotope internal standards ( 13 C 2 , 15 N-GSH and ( 13 C 2 , 15 N) 2 -GSSG/mL). 2.1.7 Analytical Method: The method of Zhang et al. (2008) for the determination of GSH and GSSG in rat liver was adapted to the measurement in forestomach tissue. Quantitation was achieved with separation via HPLC/+ESI/MS/MS. Identical conditions were used for rat and mouse tissues with the exception that the mobile phases included formic acid for rat and acetic acid for mouse. 2.1.8 Data Analyses: Descriptive statistics (i.e., mean ± standard deviation) were calculated for all relative parameters. Determination of treatment-related effects was based on sound scientific principles such as biological plausibility and comparison to concurrent and historical control data. 2.1.9 A benchmark dose (BMD) analysis established BMD and BMDL (lower limit of the 95% confidence interval on the BMD) values for GSH depletion (U.S. EPA, 2015). For continuous data, the models run were Hill, exponential, linear, polynomial and power. The benchmark response (BMR) is the response level used to calculate the BMD. A 50% difference from the control mean was run based on the Frederick et al. (1992) consideration that values greater than 50% depletion are severe. Several criteria were used to decide if the model was a good fit. weeks old at the start of treatment) was conducted to establish the dose levels for the transgenic assay (OECD Test Guideline 488, 26 July 2013). Gavage doses of EA in corn oil (3 mice/ group) for 28 days at 0, 25.0, 50.0, 100 and 200 mg/kg/day were followed by a 3 day recovery period. Necropsy followed exsanguination under isoflurane anesthesia. We observed and recorded body weights at initiation and weekly until termination, general condition daily and external and internal macroscopic examination and histopathological examination of the stomach (including forestomach) and liver at study termination. 2.2.5 Range finding: 39-week old male gpt delta mice (Japan SLC, Inc., Shizuoka, Japan) in good health were selected for use after 7 days of acclimation. 6 mice/group received daily gavage doses of 0, 8, 20 and 50 mg EA/kg/day in corn oil for 4 weeks at a volume of 10 mL/kg. The positive control mice were treated by oral gavage with B[a]P at 125 mg/kg for 5 days. The positive control animals were sacrificed 14 days after the last treatment. 2.2.6 Tissues and DNA isolation: After gross examination, liver was weighed then liver and stomach tissue portions prepared for genomic analysis were quickly frozen in liquid nitrogen and stored at −80°C; portions for histopathology were fixed in 10 vol % neutral buffered formalin. The greater curvature of the stomach was incised. The stomach contents were removed with physiological saline. The stomach section for genomic analysis (about 4 × 10 mm) included forestomach and glandular stomach. For details about genomic DNA processing see supplemental information. 2.2.7 Mutation assays: The point mutation assay was conducted according to Nohmi et al. (1996) . The phages were infected into E. coli YG6020. The mutant frequencies (gpt MFs) were calculated by dividing the number of confirmed 6-thioguanine-resistant colonies by the number of rescued plasmids. The Spi − assay was conducted according to Masumura et al. (2002 (1) the MF for the liver in the positive control group markedly increases with a statistically significant difference from the negative control group; and (2) the MF in the negative control group should be within the acceptable range calculated from the laboratory historical data. 2.2.9 Data Analyses: Bartlett's test assessed the homogeneity of MFs in the treatment groups and negative control group. Homogeneous data were analyzed using the Dunnett test. The Steel test was used for non-homogenous data. MFs between the negative control and positive control were compared by Student's t-test or AspinWelch's t-test. Five percent levels of probability were used as the criterion for significance.
Materials and methods

GSH and GSSG studies
Results
GSH/GSSG assay
In the mouse study standards of GSH and oxidized GSH (GSSG) were linear over a concentration range of 0.002-0.500 μg analyte/mL 10% aqueous TCA. The correlation coefficient (R 2 ) values for all analyses were > 0.999. High levels of background GSH and GSSG, relative to the fortification amounts, were observed in the low concentration spikes. Therefore, only the high concentration spike data were used to determine the recovery of GSH and GSSG from mouse forestomach extract. The average recoveries were 112% for GSH and 95.2% for GSSG, indicating no significant loss of analyte during sample preparation for analysis. These data showed the adequacy of this extraction technique. Measured values were not corrected. The lowest level quantitated (LLQ) for both analytes was determined to be 0.435 μg/g tissue based upon the concentration of the lowest standard analyzed, the lowest dilution factor and sample weight.
Mice: Range finding treatment of C57BL6 mice with 50 or 100 mg/ kg bw EA depleted forestomach GSH and GSSG in samples collected at 1or 3 h post-dosing. The response was similar at both time points however the variability was lower in the 3 h groups. GSH depletion was > 60% after administration of 50 mg/kg EA and ≥ 80% at 100 mg/kg. Similarly, GSSG levels fell to < 30% of control during the study. Summarized data are provided in Table 1. GLP determination of GSH depletion in forestomach: Three h after a single oral administration of EA to mice, the levels of GSH and GSSG in forestomach were significantly decreased in a dose-responsive manner (trend test, p < 0.05). The average GSH concentration in forestomach of the control mice was 532 μg/g tissue and the GSH depletions (% reduction relative to controls) were > 50% in all test groups and the GSH level in each group was significantly lower than that in the control group (p < 0.05). The average GSSG concentration in forestomach of the control mice was 34.2 μg/g tissue and the GSSG reduction was > 60% relative to controls. The GSSG level in each group was significantly lower than that in the control group (p < 0.05). The GSH/ GSSG ratio was not significantly changed in EA treated mice. However, the mole% of GSSG did decrease relative to GSH reflecting a reduction in the reserve available to regenerate intracellular GSH. Relative forestomach weights in mice were 110-114% of control value at termination, 3 h after administration of EA in corn oil. Administration of 20 mg/kg EA in corn oil caused reductions in the GSH (43%) and GSSG (26%) levels in rat forestomach. Relative forestomach weight was 105% of control value at termination, 3 h after administration. See Table 2 for summarized results.
Benchmark Dose: The only model showing a good fit was the Hill model for all endpoints. GSH was modeled with homogeneous variances while GSSG and NPSH were modeled with non-homogeneous variances. For the global goodness-of-fit test, all other models had a pvalue < 0.1 and all had at least one residual greater than 2 except the polynomial model for NPSH, thus these were not good fits. This study provided a BMD 50 of 17.7 mg/kg (BMDL 13.3) for the GSH depletion in the mouse forestomach. Using the data from deBethizy et al. (1987) the BMD 50 for NPSH depletion in the rat forestomach was 14.9 mg/kg (BMDL 13.4).
The Hill models resulting in a good fit are presented in Table 3 .
TGR assay range-finding study
No deaths occurred. Body weights and clinical signs were unremarkable (data not shown). Gross examination at necropsy revealed white nodules in the forestomach in all mice receiving 200 mg/kg/day and in one of 3 mice receiving 100 mg/kg/day. Histopathology of these animals revealed an inflammatory response in the forestomach (consisting of squamous cell hyperplasia, fibrosis of mucosa and infiltration of inflammatory cells). In addition, erosion was observed in 1 animal in the 200 mg/kg/day group. See Table 4 and Fig. 1 for details. 
TGR mutation study
No deaths occurred. No adverse effects on body weights, clinical signs of toxicity, or gross pathology were observed (data not shown). Histopathology revealed EA induced inflammatory cell infiltration (slight) in the forestomach in 2 animals in the 8 mg/kg/day group and 1 animal in the 50 mg/kg/day group (Table 5 ). There were no histopathological findings related to EA treatment in the liver.
The gpt MFs in the liver or the Spi − MFs in the liver or stomach (including forestomach) (Table 6) were not significantly increased compared to the respective negative controls. The gpt MFs in the stomach (including forestomach) were significantly decreased compared to the respective negative controls. These decreases in mutant frequency were interpreted as not treatment-related and not biologically relevant given that they were within the acceptable ranges calculated from the historical negative control data (Table 7) in the facility. The positive control, B[a]P, induced point mutations and deletions 7-fold and 4-fold higher in the liver and 4-fold and 8-fold higher in the stomach (including forestomach), respectively, than those of the negative control. Detailed presentation of the gpt and Spi − mutation frequencies (MFs) in the liver and stomach (including forestomach) induced by EA can be found in the supplemental information.
Discussion
These studies addressed data gaps in the information for proposed MOAs or AOPs for scenarios where EA exposure leads to GSH depletion resulting in strong cytotoxicity, followed by inflammation and hyperplasia. These are conditions that may lead to secondary genotoxic events. The purpose of these studies was to understand the role of GSH in determining the maximum tolerated dose (MTD) including evaluation of apical endpoints and saturation of metabolism and then to generate contemporary guideline (OECD TG-488) compliant mutation data with doses not exceeding the MTD.
If the sequence of events is: (1) exposure leads to, (2) GSH depletion, followed by (3) cytotoxicity and possibly genotoxicity, then GSH depletion would be the key event or MIE affecting the MTD. There is some comparative information in the literature related to GSH levels and cytotoxicity but the existing data, while informative, do not provide a comprehensive view due to the use of cell free and cell systems from various organs. The use of in vitro data alone can be misleading when conducting a hazard assessment. For example, comparing the EC50 for GSH depletion in the related materials methyl acrylate (MA) and methyl methacrylate (MMA) in red blood cells, MA was 40 times more potent in depleting cellular GSH than (MMA), while the cell free system showed 160 times greater reactivity (McCarthy et al., 1994) . This supports the importance of developing relevant in vivo data to provide histopathological and biochemical information regarding the KE in the hypothesized mechanism.
The knowledge base on the function of GSH in the cell has been accumulating for over 125 years (Lillig and Berndt, 2013) as has the understanding of its distribution and function within cellular compartments and organelles. Cellular systems exist to maintain the steady state balance of GSH to provide protective mechanisms to prevent cytotoxicity. GSH depletion > 50% is associated with tissue toxicity (Frederick et al., 1992) and GSH depletion is a common feature of pathways describing cytotoxicity progressing to cell death (Franco and Cidlowski, 2009; Ortega et al., 2011) . The processes from cytotoxicity to cell death can occur in the same system at different degrees depending on the redox status and other factors activated within the cells (Nagai et al., 2002) . Redox imbalance can lead to the transitioning of a cell from a quiescent to a proliferative state, arrest growth, or initiate cell death. These changes depend on the degree and duration of the imbalance. The distribution of GSH within the cellular compartments influences whether cell death occurs by apoptosis, autophagy, or necrosis. Cells are protected from some toxicants by GSH conjugation. GSH depletion increases cytotoxicity of some agents shifting the response from apoptosis to necrosis (Fernandes and Cotter, 1994; Higuchi and Yoshimoto, 2002) which can adversely affect surrounding tissue due to release of destructive enzymes resulting in irritation and inflammation (Wallach et al., 2014) . Investigations conducted after the NTP bioassays on EA were published provided information on the effects of EA exposure on tissue integrity and NPSH concentration. Dose related edema of the rat forestomach occurred 4 h after gavage administration of 100-400 mg/kg EA. Four daily doses of 200 mg/kg produced focal erosions or ulcers and forestomach mucosal hyperplasia in all rats (Ghanayem et al., 1985b) . Using comparable doses, deBethizy et al. (1987) measured effects in rat forestomach and other organs 1 h after administration of EA in corn oil. In the forestomach 0-20 mg/kg EA resulted in essentially linear NPSH depletion to 43% of control while 100 and 200 mg/kg caused maximal depletion to < 20% of control value. Significantly increased forestomach weight and gross evidence of edema were only reported at 200 mg/kg. However, the organ weight was anticipated to reach a maximum at 8 h post dosing, based on time course studies (Ghanayem et al., 1985a) . The current study used similar doses in the mouse and only one time point (3 h) for measurement of forestomach weights. Additional time points may have demonstrated a similar edematous progression.
The current study provides a BMD 50 of 17.7 mg/kg (BMDL 13.3) for GSH depletion in the mouse forestomach. The BMD 50 for NPSH depletion in the rat forestomach was 14.9 mg/kg (BMDL 13.4). In both studies the GSH depletion considered "severe" was estimated to occur at EA gavage doses of < 20 mg/kg. Figs. 2 and 3 illustrate the sharp drop in GSH concentration and similarity in changes in the slope of the curves between 20 and 100 mg/kg in both species. The BMDL point of departure value can be used as an alternative to the NOAEL, while the doses above the BMD 50 can be considered severely metabolically compromised.
The information on GSSG levels from the current study also allows an estimation of cellular redox potential using the GSH:GSSG ratio and the Nernst potential. Any change in the absolute concentration of GSH within a cell changes the redox potential, even if the GSH:GSSG ratio does not change, and reflects the potential for cells like hepatocytes which have more GSH to have a higher redox buffering capacity (Han et al., 2006; Frederick et al., 1992) . Fig. 4 shows an overall change toward oxidation using the data generated for the mouse forestomach. The Nernst equation shows a statistically significant difference from control for redox potential at 50 and 100 mg/kg. While the GSH:GSSG ratios were not significantly different in this study, the dose response curves for changes in redox status converge in the region of 50 mg/kg for the mouse forestomach. The forestomach weight increased with the increased oxidation potential, even at this early time point (Fig. 5) . The methods used in the current study did not allow for measurements of GSH and GSSG concentrations by cellular compartment. However, the edematous responses and inflammation reported in the literature for rats may reflect the initiation of necrosis rather than apoptosis in response to the redox imbalance.
Persistent inflammation has been associated with mutagenicity (Ferguson, 2010) . There is also a strong link between chronic inflammation and local and metastatic tumors (Aggarwal et al., 2006) . Sato et al. (2006) directly tested the relationship between chronic inflammation and mutagenesis, comparing the response in IL-10 deficient and normal gpt mice. The mutation response was 10x higher in the deficient mice, which develop inflammation under SPF conditions and are a model for ulcerative colitis. The mutation frequencies in a non- 10.4 6.9 NPSH (rat) 14.9 13.4 Table 4 Gross pathological and histopathological findings in range-finding study of ethyl acrylate. inflamed tissue, the liver, were similar between normal and deficient mice serving as an internal control and demonstrating that chronic inflammation in the colon promotes the generation of mutations. Both genotoxic and non-genotoxic MOAs have been proposed for the induction of forestomach tumors depending on the core genetic alterations. Some agents clearly react with DNA and involve changes in oncogenes or tumor suppressor genes. Others, including EA at irritating/cytotoxic concentrations, appear to lead to cell injury, cell proliferation and tumors through nonspecific mechanisms leading to chronic inflammation for which there is a strong link (Proctor et al., 
R. Ellis-Hutchings et al.
Regulatory Toxicology and Pharmacology 92 (2018) 173-181 2007; Aggarwal et al., 2006) . In vivo genotoxicity studies further support the current study results of a lack of mutagenicity by EA in animals. No DNA adducts were detected in the forestomach or liver of groups of 3 male Fisher 344 rats given EA gavage doses up to 400 mg/kg (Ghanayem et al., 1987) . No genotoxicity was reported in peripheral blood leukocytes from groups of female Tg. AC transgenic mice treated dermally with EA for 20 weeks (Tice et al., 1997) using the comet and micronucleus assays. No increases in micronucleus frequency were observed in the bone marrow of BDF1 mice given EA up to 1000 mg/kg by intraperitoneal injection or gavage (Morita et al., 1997) .
Current test guidelines reflect the importance of choosing the MTD carefully to maintain the integrity of the target tissues. In this mutagenicity study, the MTD was selected based on saturation of metabolism in the site of contact target organ. The high dose was appropriately set at 50 mg/kg/day because this dose is at the threshold for critical GSH depletion and controlled for the confounding effect of inflammation. The information on the redox status of the forestomach and the forestomach weights noted in the GSH study support the MTD selection in the TGR study based on properly maintaining the metabolic integrity of the target tissues. EA induced slight inflammatory cell infiltration in the forestomach in 2 animals in the 8 mg/kg/day group and 1 animal in the 50 mg/kg/day group.
Quantitative GSH depletion data in the forestomach has not been previously reported for the mouse or compared in mouse and rat forestomach. This study provides new information leading to insight on the selection of the MTD in future investigations as well as aiding interpretation of results from previously conducted studies. In practice, accepting that GSH conjugation is a major pathway for EA metabolism and its depletion following oral gavage in rodents at approximately 50 mg/kg/day exemplifies kinetic saturation, this dose should provide a guide for determining the MTD for oral studies examining forestomach effects and the consequent assessment of these effects.
Conclusions
This study demonstrated that following oral gavage of EA GSH depletion occurs in mouse forestomach tissue with a similar dose response pattern to that previously described for the rat. GSH depletion to < 50% of control was associated with acute oral gavage doses of 20 mg/kg for both species and reductions to < 20-30% of control at 100 mg/kg, spanning the range from minimal effects at 20 mg/kg to dose related increasing irritation. The measurement of GSH and GSSG allowed an estimation of cellular redox potential. Based on cellular redox changes and the observed histopathology, the GSH buffering capacity in the mouse and rat forestomach tissue appears to lose effectiveness in the region of 50 mg/kg. This current GLP and OECD TG-488 guideline-compliant study demonstrated that no increases in point mutations or deletions occurred following treatment of gpt delta transgenic mice up to 50 mg/kg/day, providing an important addition to the in vivo genotoxicity profile of EA.
The quantitation of GSH depletion allowed the definition of the toxicity MTD to be defined based on saturation of metabolism. This step should be considered the MIE or initial KE in the forestomach tumor MOA of EA in rodents. Especially relevant for EA is the reassessment of the threshold leading to critical GSH depletion, followed by inflammation, cytotoxicity, and hyperplasia. These results provide valuable information for use in evaluating molecular initiating events in AOP or KE in MOA frameworks for EA and other GSH depleting materials. R. Ellis-Hutchings et al. Regulatory Toxicology and Pharmacology 92 (2018) 173-181 
